AN2 Therapeutics, Inc. (ANTX) Ratings Upgrade: Growth Potential Ahead

On May 14, 2026, AN2 Therapeutics, Inc. (ANTX) received an optimistic rating upgrade to “Outperform” from Joseph Schwartz of Leerink Partners. This pivotal change, paired with a price target of $9, marks an encouraging outlook for investors currently evaluating the biopharmaceutical sector.

Market / Price Action

In recent trading sessions, ANTX’s stock has displayed notable volatility, closing at $4.64, which represents a $0.33 increase, or approximately 7.66%, in just one day. The stock has navigated a tumultuous range over the past year, with a 52-week high of $6 and a low of $4.64. Despite this volatility, the company’s market capitalization stands at approximately $127.15 million, indicating a relatively stable company profile within a fluctuating market. Notably, ANTX’s beta stands at -0.96, suggesting that the stock tends to move inversely to market trends—an aspect that could attract risk-averse investors seeking a hedge against broader market volatility.

Short- and Long-Term Performance

When examining the stock’s performance across various timeframes, the recent trends appear mixed. Over the past 30 days, ANTX has shown a modest increase of 4.42%. However, this is contrasted by a slight decline of 0.84% over the last quarter and a more concerning drop of 7.09% over the past year. The stock has exhibited weekly volatility of 8.99% and monthly volatility of 8.82%, reflecting investor nervousness in the current market environment. Trading volume further indicates fluctuation, with an average volume of 1,534,639 over three months, while the past ten days averaged at 241,872 shares traded, suggesting an increase in interest from investors, particularly in the wake of the recent analyst rating upgrades.

Earnings / Financials

The company’s earnings history reveals a nuanced yet pivotal moment in its financial performance. In its latest reporting on May 11, 2026, ANTX reported earnings per share (EPS) of -$0.29, which fell short of the estimated -$0.23 by approximately 26.09%. This marks an increase in the EPS surprise factor from the previous reporting period, where the actual EPS also landed at -$0.29, though it exceeded estimates by 20.83%. These figures highlight ongoing challenges for the company in achieving profitability, underlining the importance of continued scrutiny over its financial path and market responses moving forward.

Analyst / Consensus View

The recent consensus surrounding ANTX is decidedly cautious yet optimistic. With only one analyst rating available, the sentiment is entirely bullish; the stock currently holds a “Buy” rating from Schwartz, who has set a price target that aligns with the overall analyst expectations at $9. This target implies a significant upside potential when considering the stock’s current price, fostering a robust environment for potential growth, should the company meet or exceed market expectations in forthcoming quarters.

Stock Grading or Fundamental View

The Stocks Telegraph grading score for AN2 Therapeutics stands at 60, indicating moderate health and viability in terms of market metrics and underlying financial analysis. This score reflects a blend of strengths in operational performance and potential growth opportunities, while also recognizing inherent risks typical within the biopharmaceutical sector, particularly given the uncertain nature of pending drug approvals and clinical trials.

Conclusion

For investors contemplating an entry point into AN2 Therapeutics, the stock presents an intriguing profile that may suit those interested in long-term growth opportunities within the biopharmaceutical field. The recent analyst upgrade underscores a potential upswing in investor interest, buoyed by a promising price target. However, the ongoing losses highlight the need for caution. Investors should weigh the risks associated with emerging companies against the anticipated long-term benefits. As ANTX navigates its financial trajectory, staying informed about its developments will be crucial for stakeholders aiming for a balanced investment strategy in this volatile yet promising sector.